Switch theme
Sign up to access all valuation multiples
Hybio Pharmaceutical Co Ltd is engaged in manufacturing and sale of peptide products. The company's peptide finished dosage products include digestive system agents, immune modulators, hormone and endocrine modulators, antiviral agents, and hemostatic products. It also provides peptide CRO and CMO services, as well as API products.
2003
n/a
LTM Revenue $106M
LTM EBITDA $60.7M
$1.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Hybio Pharmaceutical has a last 12-month revenue of $106M and a last 12-month EBITDA of $60.7M.
In the most recent fiscal year, Hybio Pharmaceutical achieved revenue of $59.4M and an EBITDA of -$32.4M.
Hybio Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hybio Pharmaceutical valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $59.4M | $81.3M | XXX | XXX | XXX |
| Gross Profit | $73.1M | $75.0M | XXX | XXX | XXX |
| Gross Margin | 123% | 92% | XXX | XXX | XXX |
| EBITDA | -$32.4M | $36.0M | XXX | XXX | XXX |
| EBITDA Margin | -54% | 44% | XXX | XXX | XXX |
| Net Profit | $4.2M | -$51.1M | XXX | XXX | XXX |
| Net Margin | 7% | -63% | XXX | XXX | XXX |
| Net Debt | $217M | $170M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Hybio Pharmaceutical's stock price is CNY 13 (or $2).
Hybio Pharmaceutical has current market cap of CNY 11.9B (or $1.6B), and EV of CNY 13.6B (or $1.9B).
See Hybio Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.9B | $1.6B | XXX | XXX | XXX | XXX | $-0.00 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Hybio Pharmaceutical has market cap of $1.6B and EV of $1.9B.
Hybio Pharmaceutical's trades at 17.7x LTM EV/Revenue multiple, and 30.8x LTM EBITDA.
Analysts estimate Hybio Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Hybio Pharmaceutical and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.9B | XXX | XXX | XXX |
| EV/Revenue | 23.0x | XXX | XXX | XXX |
| EV/EBITDA | 52.0x | XXX | XXX | XXX |
| P/E | -65.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpHybio Pharmaceutical's NTM/LTM revenue growth is 72%
Hybio Pharmaceutical's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Hybio Pharmaceutical's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Hybio Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Hybio Pharmaceutical and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 37% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 44% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -211% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 116% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 51% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 7% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 37% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 115% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Suven Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hybio Pharmaceutical acquired XXX companies to date.
Last acquisition by Hybio Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Hybio Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Hybio Pharmaceutical founded? | Hybio Pharmaceutical was founded in 2003. |
| Where is Hybio Pharmaceutical headquartered? | Hybio Pharmaceutical is headquartered in China. |
| Who is the CEO of Hybio Pharmaceutical? | Hybio Pharmaceutical's CEO is Ms. Yu Pinxiang. |
| Is Hybio Pharmaceutical publicy listed? | Yes, Hybio Pharmaceutical is a public company listed on SHE. |
| What is the stock symbol of Hybio Pharmaceutical? | Hybio Pharmaceutical trades under 300199 ticker. |
| When did Hybio Pharmaceutical go public? | Hybio Pharmaceutical went public in 2011. |
| Who are competitors of Hybio Pharmaceutical? | Similar companies to Hybio Pharmaceutical include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Hybio Pharmaceutical? | Hybio Pharmaceutical's current market cap is $1.6B |
| What is the current revenue of Hybio Pharmaceutical? | Hybio Pharmaceutical's last 12-month revenue is $106M. |
| What is the current EBITDA of Hybio Pharmaceutical? | Hybio Pharmaceutical's last 12-month EBITDA is $60.7M. |
| What is the current EV/Revenue multiple of Hybio Pharmaceutical? | Current revenue multiple of Hybio Pharmaceutical is 17.7x. |
| What is the current EV/EBITDA multiple of Hybio Pharmaceutical? | Current EBITDA multiple of Hybio Pharmaceutical is 30.8x. |
| What is the current revenue growth of Hybio Pharmaceutical? | Hybio Pharmaceutical revenue growth between 2023 and 2024 was 37%. |
| Is Hybio Pharmaceutical profitable? | Yes, Hybio Pharmaceutical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
